While markets got a rough start to the week on the heels of the UK Referendum vote, both US and global markets rebounded sharply during the remainder of the week. The S&P 500 closed the week at 2,103, just ten points shy of its close before the vote....read more
Syros Pharmaceuticals, which is developing gene expression therapies based on non-coding DNA research, raised $50 million by offering 4 million shares at $12.50, below the range of $14 to $16. Syros Pharmaceuticals plans to list on the Nasdaq under the symbol...read more
In the last week before Independence Day weekend, there are a few small IPOs to cap off a second quarter that was much improved from the lackluster first quarter. Syros Pharmaceuticals looks to continue the trend of insider buying on biotechs....read more
Syros Pharmaceuticals, which is developing small-molecule genetic therapies targeting leukemia, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to $16....read more
US IPO Weekly Recap: 2 deals price; markets shake off UK vote
While markets got a rough start to the week on the heels of the UK Referendum vote, both US and global markets rebounded sharply during the remainder of the week. The S&P 500 closed the week at 2,103, just ten points shy of its close before the vote....read more
Looking to fight leukemia: Syros Pharmaceuticals prices IPO at $12.50, below the range
Syros Pharmaceuticals, which is developing gene expression therapies based on non-coding DNA research, raised $50 million by offering 4 million shares at $12.50, below the range of $14 to $16. Syros Pharmaceuticals plans to list on the Nasdaq under the symbol...read more
US IPO Week Ahead: Two biotechs, one device maker and one health care REIT
In the last week before Independence Day weekend, there are a few small IPOs to cap off a second quarter that was much improved from the lackluster first quarter. Syros Pharmaceuticals looks to continue the trend of insider buying on biotechs....read more
Looking to fight leukemia: Syros Pharmaceuticals sets terms for $60 million IPO
Syros Pharmaceuticals, which is developing small-molecule genetic therapies targeting leukemia, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to $16....read more